Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,367,560
  • Shares Outstanding, K 21,100
  • Annual Sales, $ 108,970 K
  • Annual Income, $ -1,640 K
  • 36-Month Beta 0.91
  • Price/Sales 26.29
  • Price/Cash Flow 161.26
  • Price/Book 8.14

Price Performance

See More
Period Period Low Period High Performance
1-Month
134.85 +20.96%
on 12/26/17
164.67 -0.95%
on 01/23/18
+27.66 (+20.42%)
since 12/22/17
3-Month
126.50 +28.94%
on 12/01/17
164.67 -0.95%
on 01/23/18
+19.63 (+13.68%)
since 10/23/17
52-Week
95.08 +71.55%
on 02/24/17
164.67 -0.95%
on 01/23/18
+60.14 (+58.41%)
since 01/23/17

Most Recent Stories

More News
Ligand Pharm Set to Possibly Pullback After Yesterday's Rally of 2.58%

Ligand Pharm (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $155.97 to a high of $160.33. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of...

LGND : 163.11 (+2.20%)
Ligand Enters into Worldwide OmniAb(R) Platform License Agreement with Ferring Pharmaceuticals

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb platform license agreement with Ferring Pharmaceuticals. Under the license, Ferring will...

LGND : 163.11 (+2.20%)
Ligand (LGND) Inks Deal With Glenmark for OmniAb Platform

Ligand (LGND) enters into a worldwide license agreement with Glenmark for OmniAb platform.

LGND : 163.11 (+2.20%)
MRK : 61.70 (+0.73%)
NVS : 87.21 (+0.24%)
PFE : 36.82 (-0.30%)
Ligand Enters into Worldwide OmniAb(R) Platform License Agreement with Glenmark Pharmaceuticals

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered a worldwide OmniAb platform license agreement with Glenmark Pharmaceuticals. Under the license, Glenmark will be...

LGND : 163.11 (+2.20%)
Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer

Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.

SGMO : 20.00 (+3.09%)
LGND : 163.11 (+2.20%)
ONCE : 56.55 (-1.39%)
GWPH : 139.71 (+4.46%)
SGEN : 56.76 (+0.83%)
UTHR : 142.72 (-0.52%)
BIIB : 346.75 (-0.26%)
Ligand Earns $6 Million as OmniAb Partner Out-Licenses Antibody Projects

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner HanAll Biopharma successfully out-licensed antibody projects that were discovered by HanAll using Ligand's OmniAb(R)...

LGND : 163.11 (+2.20%)
Medicines Company to Sell Infectious Disease Unit to Melinta

The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.

MLNT : 14.95 (-0.33%)
LGND : 163.11 (+2.20%)
MDCO : 30.47 (+5.76%)
ACAD : 30.32 (+4.80%)
Is GW Pharma (GWPH) Likely to Beat Earnings Estimates in Q4?

GW Pharma (GWPH) will report its fiscal fourth-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.

SGMO : 20.00 (+3.09%)
LGND : 163.11 (+2.20%)
CATB : 1.55 (unch)
GWPH : 139.71 (+4.46%)
Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)

The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.

LGND : 163.11 (+2.20%)
RHHBY : 30.6600 (-0.42%)
ALKS : 59.19 (+2.72%)
BIIB : 346.75 (-0.26%)
Merck Announces $10 Billion Buyback, Hikes Dividend by 2.1%

Merck (MRK) rewards shareholders with a hike in quarterly dividend. Also, the company's board of directors sanctions a new stock buyback plan.

LGND : 163.11 (+2.20%)
ACHN : 2.99 (-0.66%)
JNJ : 141.83 (-4.26%)
MRK : 61.70 (+0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is in the Top 1%. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Key Turning Points

2nd Resistance Point 164.57
1st Resistance Point 162.08
Last Price 163.11
1st Support Level 156.54
2nd Support Level 153.49

See More

52-Week High 164.67
Last Price 163.11
Fibonacci 61.8% 138.09
Fibonacci 50% 129.88
Fibonacci 38.2% 121.66
52-Week Low 95.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.